Previously, the only way a Medicare patient could access semaglutide was if they had a type 2 diabetes diagnosis, in which case their doctor could prescribe Ozempic (semaglutide at the 0.5 mg, 1 mg, or 2 mg dose approved for diabetes)
The cardiovascular benefits are also comparable, and in some respects superior
NAD+ is an oxidizing agent in cellular metabolism, while NADH is a metabolic reducing agent
Please keep this in mind if you plan to experiment with GHK-Cu, but here's some general information from forums and studies
Once activated, either by naturally occurring GLP-1 or semaglutide, these receptors, when triggered, do several things: Lower blood glucose levels: Semaglutide mimics GLP-1's role in regulating blood glucose, effectively lowering blood sugar after a meal